drugset / Trial / NCT02234050

Trabectedin for Recurrent Grade II/III Meningioma

NCT02234050

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.

Timeline

Start
2015-07
Primary completion
2017-07
Completion
2019-01-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Trabectedin Small molecule 1.5 mg/m2

Indications